Dr Reddy's launches anti-epileptic medicine in the US market

The product is a generic equivalent of Lamictal ODT in the US; Lamictal ODT is a registered trademark of GSK group

Dr Reddy's Laboratories announced today that it has launched Lamotrigine Orally Disintegrating Tablets in 25 mg, 50 mg, and 200 mg in the US market following the approval from the US Food and Drug Administration (USFDA).

The product, an anti-epileptic medicine, is a therapeutic equivalent generic version of Lamictal ODT in the United States. Lamictal ODT is a registered trademark of GSK group of companies.

The Lamictal ODT brand and generic had US sales of approximately $65.5 million for the recent twelve months ending in July 2016, the company said quoting the IMS data.